September 14, 2018 Bio/Pharma/CRO Life Science Tools M&A, Partnerships

Horizon Discovery Edit-R crRNA libraries adopted by AstraZeneca as part of its functional genomics discovery platform

Location: Cambridge, UK 14/09/2018 AstraZeneca joins Horizon’s Genomics Discovery Initiative CRISPR knockout and activation libraries are a key toolset in early research crRNA libraries are an efficient and convenient platform for gain- and loss-of-function studies Cambridge, UK, 14 September 2018: Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene... Read more

August 28, 2018 Life Science Tools M&A, Partnerships

Horizon Discovery announces collaboration with major pharmaceutical company on single cell RNAseq-linked CRISPR screening

Location: Cambridge, UK 28/08/2018 Co-development and implementation of a new CRISPR-based screening technology platform to address critical gaps in target ID and validation Single cell RNAseq-linked pooled CRISPR screening offers unparalleled depth of screening data and biological insight New platform will further enhance Horizon’s CRISPR screening capabilities Cambridge, UK, 28 August 2018: Horizon Discovery Group... Read more

May 8, 2018 Life Science Tools PR/Corporate

Horizon Discovery appoints Terry Pizzie as Chief Executive Officer

Location: Cambridge, UK 08/05/2018 Cambridge, UK, 8 May 2018: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Group” or “the Company”), a global leader in gene editing and gene modulation technologies, is pleased to announce the appointment of Terry Pizzie as Chief Executive Officer and Board Director with immediate effect. Terry joined Horizon Discovery in 2017... Read more

March 26, 2018 Life Science Tools Product Launch

Horizon Discovery introduces whole human genome arrayed libraries to support CRISPR activation screening

Location: Cambridge 26/03/2018 First-to-market Edit-R CRISPRa arrayed crRNA libraries enable native gene overexpression for high-throughput gain-of-function screening Available as small gene families, bespoke collections, the druggable genome, or human genome-wide collection Cambridge, UK, 26 March 2018: Horizon Discovery (LSE: HZD) (“Horizon” or the “Company”), a global leader in the application of gene editing and gene modulation... Read more

March 16, 2018 Clinical Research/Diagn. M&A, Partnerships

Horizon Discovery and Genewell Biotechnology enter into partnership for distribution of diagnostic reference standards for the Chinese market

Location: Cambridge 16/03/2018 Partnership immediately provides Horizon with deeper access to Chinese diagnostic assay manufacturers and potential OEM agreements as part of stated global leadership strategy Genewell to pursue CFDA approval of Horizon reference standards for broad distribution into Chinese clinical laboratory market Cambridge, UK, and Shenzhen, China, 16 March 2018: Horizon Discovery Group plc... Read more

February 12, 2018 Cell Analysis Tools Licensing, IP, and Legal M&A, Partnerships

Horizon Discovery Enters into License Agreement with US Immuno-Oncology Company

Location: Cambridge 12/02/2018 Horizon out-licenses proprietary cell line and Helitron transposon gene editing technologies demonstrating Horizon’s ability to generate revenues from internally derived IP Horizon retains commercial rights over improvements to its technology platforms to develop new cell line technologies and gene delivery IP that can be licensed to customers for applications in biomanufacturing, diagnostic... Read more